Croda is highlighting the recent launch of Zenakine, a biotech-based neuroactive ingredient designed to counteract the effects of stress on the skin.
The novel ingredient is based on discoveries made by the translational dermatology team at the University of Manchester, UK and subsequently developed by SkinBiotherapeutics plc, an AIM listed company focused on skin health.
As commercial and manufacturing partners, Croda first introduced this cutting edge active earlier this year – through a dedicated process at concept line, including a night cream developed specifically for clinical tests – at in-cosmetics Global, the world’s largest cosmetics ingredients exhibition.
The creation of this active ingredient marks a new era in neurocosmetic skincare innovation being formulated to restore emotional balance and enhance skin vitality.
Zenakine is a high-performance active ingredient that supports the skin’s natural response to stress, working in sync with the skin’s natural biological rhythms, enhancing melatonin production to help improve sleep quality, help combat stress ageing and support wellbeing.
Susanna Casas, Managing Director, Sales & Customer Service Sales at Croda, said: “Zenakine exemplifies our strategy to deliver differentiated, science-led solutions in high-growth markets. It strengthens our premium beauty actives portfolio and reflects our commitment to innovation, efficacy and sustainability at its core.”
Fully biodegradable and compliant with COSMOS and RSPO standards, it is the latest addition to Croda’s portfolio of sustainable actives, developed using renewable feedstocks and designed to meet the highest standards of environmental stewardship.
